CML-330: Incidence of Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated with First-Line (1L) Tyrosine Kinase Inhibitors (TKI) in SIMPLICITY: An Observational Study

Abstract

Context Evidence suggests that common CV risk factors (obesity, diabetes status, age, etc.), combined with TKI therapy, may contribute to CV events in patients with CP-CML. Furthermore, CV events occurring in patients with CP-CML are often associated with significant morbidity, mortality, and healthcare resource utilization. Objective To assess the incidence of CV-related hospitalizations, subsequent length of stay (LOS), and associated costs among patients with CP-CML in a real-world setting. Design Retrospective observational study. Setting SIMPLICITY is an ongoing observational study of patients with CP-CML in Europe and the U.S. who are treated with 1L TKIs. Patients from the U.S. cohort were included in this analysis. Interventions Dasatinib (DAS), imatinib (IM), nilotinib (NIL). Main outcome measures Incidence of CV-related hospitalizations and LO, adjusted per 1000 patient-years (PY) of follow-up. Mean total hospitalization costs for each CV event were analyzed; these results will be described in the poster. Results In all, 808 patients received 1L TKI therapy: IM (n=243), DAS (n=301), or NIL (n=264). Median follow-up was approximately 4 years (48.7–51.3 months). Age, treatment center type, duration of therapy, and baseline fatigue differed significantly among the groups (P Conclusions In this real-world study of CP-CML patients, assessment of CV-related hospitalizations and LOS showed that most hospitalizations occurred within 18 months of 1L TKI initiation. The incidence of CV-related hospitalizations and LOS were descriptively lowest among patients receiving dasatinib. CV-risk profile and comorbidities should be taken into account prior to 1L TKI therapy initiation. Funding BMS.